Related Experiment Videos
Diabetes
1Department of Cardiology, London Chest Hospital, London, UK.
Insights
Diabetes significantly increases cardiovascular risk and mortality. Recent trials highlight blood pressure control, ACE inhibitors, and insulin therapy as key strategies to reduce this risk in diabetic patients.
Area of Science:
- Cardiology
- Diabetology
- Endocrinology
Background:
- Diabetes profoundly increases cardiovascular morbidity and mortality.
- Autonomic neuropathy in diabetes can mask or alter cardiac pain perception, delaying critical treatment.
- Accelerated atherogenesis in diabetes remains a significant clinical challenge.
Purpose of the Study:
- To review the cardiovascular complications of diabetes.
- To highlight recent therapeutic advances in managing cardiovascular risk in diabetic patients.
- To emphasize the importance of risk factor modification and novel treatment strategies.
Main Methods:
- Review of landmark clinical trials including UKPDS, HOPE, and DIGAMI.
- Analysis of evidence-based cardiovascular risk reduction strategies in diabetes.
- Examination of the impact of autonomic neuropathy on cardiac symptom presentation.
Main Results:
- Recent trials identified blood pressure control and converting enzyme inhibition as crucial for reducing cardiovascular risk in diabetes.
- Insulin therapy demonstrated value in reducing mortality in diabetic myocardial infarction.
- Established risk factor modification, while important, may not offer additional protection beyond that in non-diabetics.
Conclusions:
- Novel strategies, particularly blood pressure management and ACE inhibitors, are vital for cardiovascular risk reduction in diabetes.
- Insulin therapy is a key intervention for diabetic myocardial infarction mortality.
- Ongoing research is essential to further refine cardiovascular management for the growing diabetic population.
Abstract:
The causes of accelerated atherogenesis in diabetes are unclear but the consequences in terms of cardiovascular morbidity and mortality are profound. Thus diabetes not only increases the risk of coronary heart disease but also increases the case fatality rate, ensuring that the majority of patients die of cardiovascular causes, often before the age of 50 years. The problem is compounded by autonomic neuropathy which alters the perception of cardiac pain, attenuating symptoms which are often atypical or absent. This may delay presentation or lead to inappropriate triage decisions such that access to defibrillators and specific treatment is denied. Central to the cardiovascular management of diabetes is vigorous risk factor modification although clear evidence that this leads to extra protection against coronary heart disease beyond that achieved in non-diabetic individuals has not been forthcoming. In other respects too, the management of diabetic patients with heart disease is underpinned by the same evidence-base as applies to non-diabetic patients, and it is noteworthy that 15-20% of the patients in most of the landmark clinical trials have been diabetic. Recently, however, trials such as the United Kingdom Prospective Diabetes Study (UKPDS), the Heart Outcomes Prevention Evaluation (HOPE) study, and the Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study have identified novel strategies for reducing cardiovascular risk in diabetes. These trials have already had a major impact on cardiological practice, emphasising the prime importance of blood pressure control and converting enzyme inhibition for reducing cardiovascular risk in diabetes as well as the value of insulin therapy for reducing mortality in diabetic myocardial infarction. Additional trials, already in progress, are expected to refine further the cardiovascular management of patients with diabetes in order to provide an effective challenge for a problem that shows no signs of going away.